olaparib (Lynparza)

following a full submission assessed under the orphan equivalent medicine process:

olaparib (Lynparza®) is accepted for use within NHSScotland.

Indication under review: in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

In a phase III study, maintenance treatment with olaparib plus bevacizumab significantly prolonged progression-free survival (PFS) compared with placebo plus bevacizumab in patients with advanced ovarian cancer who responded to first-line standard therapy including bevacizumab.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.